Autorisation d’accès précoce refusée à la spécialité FASENRA (benralizumab) dans l’indication « traitement des patients adultes atteints de granulomatose éosinophilique avec polyangéite et non répondeurs à mépolizumab».
See also
HAS opinions and decisions
30/08/2024
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
mjhXXCzuT33M16rB
